Home › Compare › OTIC vs XYLD

OTIC vs XYLD: Dividend Comparison 2026

OTIC yields 23529.41% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OTIC wins by $263656825893602263040.00M in total portfolio value
10 years
OTIC
OTIC
● Live price
23529.41%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$263656825893602263040.00M
Annual income
$261,470,826,952,048,300,000,000,000.00
Full OTIC calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — OTIC vs XYLD

📍 OTIC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOTICXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OTIC + XYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
OTIC pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OTIC
Annual income on $10K today (after 15% tax)
$2,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$222,250,202,909,241,040,000,000,000.00/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, OTIC beats the other by $222,250,202,909,241,040,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OTIC + XYLD for your $10,000?

OTIC: 50%XYLD: 50%
100% XYLD50/50100% OTIC
Portfolio after 10yr
$131828412946801131520.00M
Annual income
$130,735,413,476,024,150,000,000,000.00/yr
Blended yield
99.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on OTIC right now

OTIC
Analyst Ratings
3
Buy
2
Hold
1
Sell
Consensus: Buy
Price Target
$6.00
+70488.2% upside vs current
Range: $6.00 — $6.00
Altman Z
-16.9
Piotroski
2/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OTIC buys
0
XYLD buys
0
No recent congressional trades found for OTIC or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOTICXYLD
Forward yield23529.41% ✓10.98%
Annual dividend / share$2.00$4.30 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$263656825893602263040.00M ✓$25.3K
Annual income after 10y$261,470,826,952,048,300,000,000,000.00 ✓$3,219.02
Total dividends collected$263512773352864874496.00M ✓$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: OTIC vs XYLD ($10,000, DRIP)

YearOTIC PortfolioOTIC Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$2,363,641$2,352,941.18$10,818$1,098.39+$2.35M → OTIC
2$522,296,260$519,767,163.60$11,738$1,222.51+$522.28M → OTIC
3$107,898,570,132$107,339,713,133.69$12,774$1,364.64+$107898.56M → OTIC
4$20,839,539,403,669$20,724,087,933,628.63$13,944$1,527.86+$20839539.39M → OTIC
5$3,763,094,738,299,595$3,740,796,431,137,668.50$15,270$1,715.87+$3763094738.28M → OTIC
6$635,328,756,192,409,300$631,302,244,822,428,800.00$16,775$1,933.09+$635328756192.39M → OTIC
7$100,290,713,829,320,920,000$99,610,912,060,195,030,000.00$18,490$2,184.87+$100290713829320.91M → OTIC
8$14,802,844,275,710,542,000,000$14,695,533,211,913,168,000,000.00$20,450$2,477.63+$14802844275710542.00M → OTIC
9$2,042,989,665,003,715,000,000,000$2,027,150,621,628,704,700,000,000.00$22,697$2,819.19+$2042989665003714816.00M → OTIC
10$263,656,825,893,602,270,000,000,000$261,470,826,952,048,300,000,000,000.00$25,280$3,219.02+$263656825893602263040.00M → OTIC

OTIC vs XYLD: Complete Analysis 2026

OTIC — Stock

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Full OTIC Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this OTIC vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OTIC vs SCHDOTIC vs JEPIOTIC vs OOTIC vs KOOTIC vs MAINOTIC vs QYLDOTIC vs JEPQOTIC vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.